On February 14, Merck announced the interim results of the Ib/II umbrella study KEYNOTE-365 at the American Society of Clinical Oncology Urology Tumor Symposium (ASCO GU). KEYNOTE-365 is a developmental, multicenter, multi-cohort, non-randomized study evaluating the efficacy of a fixed dose of Keytruda (200 mg once every 3 weeks)… Continue Reading Merck initiates the largest clinical trial of PD-1/PD-L1 prostate cancer
In early June, some media reported that Merck, the world’s oldest pharmaceutical company, will soon celebrate its 350th birthday. The most wanted gift is the Chinese market! A few days ago, this veteran pharmaceutical company found a new business partner – Ali Health. On June 20, Merck and Ali signed… Continue Reading In order to get a 350th birthday gift, old Merck found a “little fresh meat.”
The American Society of Clinical Oncology (ASCO) annual meeting is the most important meeting in the annual oncology field. The data published in the ASCO annual meeting not only can affect the clinical treatment of cancer patients, the stock price of the relevant pharmaceutical company may also fluctuate strongly with… Continue Reading Who is ASCO’s biggest winner this year?
Viagra From the failure of cardiovascular medications to the great success of ED indications In the 1980s, scientists at Pfizer’s European Research Center have been looking for drugs to treat cardiovascular diseases such as angina. The commonly used nitrates at that time were prone to tolerance. At that time, basic… Continue Reading How did innovative drugs fail from Viagra to PD-1?
Dengue fever is a mosquito-borne viral infection that resembles flu and can develop into a fatal complication, namely severe dengue fever. The incidence of dengue fever has risen rapidly, mainly in the tropical and subtropical regions. About half of the world’s population is at risk of dengue fever. In some… Continue Reading Observing the Difficult Development Course of Dengue Fever Vaccine from the Rise and Fall of Dengvaxia